Skip to main content

FDA recall, , Moderate risk

Pipeline Flex Embolization Device with Shield Technology

Incorrect labeling - embolization devices labeled as 3.0 mm x 20 mm implants contain 12 mm implants, and devices labeled as 3.0 mm x 12 mm implants contain 20 mm implants.

What happened

Micro Therapeutics, Inc., of Irvine, California, began a recall on June 8, 2026, of Pipeline Flex Embolization Device with Shield Technology products due to incorrect labeling: devices labeled as 3.0 mm x 20 mm implants contain 12 mm implants, and devices labeled as 3.0 mm x 12 mm implants contain 20 mm implants.

The FDA added the recall to its Enforcement Report on July 22, 2026, and included it in the weekly enforcement report on July 29, 2026. Distribution was nationwide in the states of CT, DE, IN, MA, NC, NJ, NM, NY, OH, PA, TX, VA, and WA.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

2 products

Affected if its UDI-DI is listed.

A UDI-DI is the device identifier printed with the barcode on the device label.

  1. Pipeline Flex Embolization Device with Shield Technology, 3.00 mm x 20 mm 027 REF PED2-300-20

    UDI-DI
    • 00763000448844
  2. Pipeline Flex Embolization Device with Shield Technology, 3.00 mm x 12 mm 027 REF PED2-300-12

    UDI-DI
    • 00763000448806

Recall details

Company began the recall
Company
Micro Therapeutics, Inc.Irvine, California
Risk

Moderate risk

Using it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
99326
Recall numbers
Z-2773-2026 to Z-2774-2026

All recalls from Micro Therapeutics, Inc.

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)